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Unknown until recently, the genus Emergomyces is composed of dimorphic fungi with human
pathogenic potential. Five described species have been implicated as causes of disease in
immunocompromised persons on at least 4 continents. In some regions, such as southern
Africa, this disease, emergomycosis, is now the most commonly diagnosed dimorphic fungal
infection. Herein, we review the history of these fungi, clinical features and pathogenesis of
disease, what is known of their biology, and future research directions.
Origin story and current status
In 1994, an Italian woman with advanced HIV disease and widespread cutaneous lesions was
diagnosed with an atypical disseminated mycosis. A biopsy of skin tissue demonstrated small
budding yeasts, resembling those of Histoplasma capsulatum, in addition to larger pleomor-
phic cells. Moreover, the fungus that grew in culture had a dissimilar microscopic appearance
[1, 2]. The conidia were arranged in complex “florets” on slightly swollen stalks reminiscent of
Emmonsia crescens or Ea. parva, fungi for which the thermodependent phase is characterized
by swollen, thick-walled, nonreplicating cells called adiaspores, usually observed in the lungs
of small terrestrial mammals in a disease called adiaspiromycosis [3]. Genetic analysis sug-
gested the clinical isolate was related to Ea. crescens, and the fungus was therefore described in
1998 as Ea. pasteuriana [2].
In 2013, following the introduction of molecular identification procedures in some South
African laboratories, a dimorphic fungus most closely related to Ea. pasteuriana was found to
be the cause of a disseminated mycosis in patients with advanced HIV disease [4]. Since then,
infection with this fungus has been established to comprise the most frequently diagnosed
dimorphic mycosis in South Africa [5–7]. In light of these reports, global collections were re-
examined for dimorphic Emmonsia-like fungi. Archived isolates were examined
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phenotypically and with genetic analyses based on ribosomal DNA sequences, ultimately lead-
ing to a taxonomic revision within the family Ajellomycetaceae [8, 9]. In brief, Ea. parva, the
type species of Emmonsia, was transferred to the genus Blastomyces (as B. parvus), and the
genus Emmonsia was more narrowly defined to include Ea. crescens and Ea. soli, the latter cur-
rently known only from soil [8, 9]. A new genus, Emergomyces, was created to accommodate
Emmonsia-like systemic dimorphic pathogens related to Es. pasteurianus (formerly Ea. pas-
teuriana) and characterized in the thermodependent phase by small yeast cells with narrow-
based buds [8, 9].
Five species are now described within Emergomyces [8, 9], and cases of disease have been
reported globally (Fig 1). Es. pasteurianus, the type species, has been reported from Europe
(including from Italy [1], Spain [10], France [ex-Georgia] [11], and the Netherlands [12]), Asia
(China [13, 14] and India [ex-Nepal] [15]) and Africa (Uganda [ex-Rwanda] [16] and South
Africa [9]). Es. africanus has been reported from South Africa and Lesotho [4, 9]. Es. canaden-
sis has been reported from Canada (Saskatchewan) and the United States (Colorado and New
Mexico) [17]. Es. orientalis has been reported from China [18], and Es. europaeus has been
reported once from Germany [19].
Fig 1. Global geographic distribution of reported cases of emergomycosis [1, 4–7, 10–19, 28–30]. Each icon represents a single case except for Emergomyces africanus
in South Africa, as indicated. Map created by Institute of Tropical Medicine, Antwerp.
https://doi.org/10.1371/journal.ppat.1007977.g001
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The earliest known isolate among these Emergomyces species was from 1992 [17]. It remains
unclear if these fungi have truly emerged or whether they are only now recognized because of an
increase in the number of susceptible hosts, improved microbiology capacity, and/or the wide-
spread adoption of molecular identification techniques in clinical and research laboratories.
Ecology
As with other systemic dimorphic fungi, infection is presumed to occur from inhalation of
conidia, followed by a temperature-dependent transformation to a yeast-like phase that is
capable of causing disease and of extrapulmonary dissemination (Fig 2).
Studies in search of an environmental reservoir for Emergomyces species have focused on
Es. africanus in South Africa due to the large number of cases there [20–22]. Es. africanus
Fig 2. Potential model for exposure and pathogenesis of Emergomyces. 1) Emergomyces species exist in soil in a mold phase, from where
2) conidia are released and aerosolized. 3) Upon inhalation by humans, the conidia undergo a temperature-dependent transformation in the
lungs to yeast-like cells that replicate by budding and are capable of causing pulmonary disease in susceptible individuals. 4) Yeast-like cells
disseminate hematogenously in macrophages throughout the body, causing extrapulmonary disease. 5) Cutaneous disease is most frequently
reported, although virtually any body site can be affected.
https://doi.org/10.1371/journal.ppat.1007977.g002
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DNA was detected in 30% of soil samples tested in the Western Cape Province, including from
a wide range of soil habitats, such as soils associated with human activities like agriculture and
horticulture and soils associated with plants endemic to the Cape Floral Kingdom. However,
to date, the fungus has not been successfully isolated in culture from the environment, even
with passage of soils through mice [20]. Es. africanus DNA was also detected in 10% of air sam-
ples collected in an urban location in the Cape Town metropole [21]. Naturally occurring
infections of animals have not been demonstrated [22].
Emergomycosis
Disease caused by Emergomyces infection has been called emergomycosis (formerly dissemi-
nated emmonsiosis), and similarities have been noted among cases caused by different species.
In general, patients with reported emergomycosis have been immunocompromised, including
with HIV infection, solid organ transplantation, hematological malignancies, and immuno-
suppressant use [23]. Most patients with Es. africanus infection have had cutaneous lesions,
which most commonly appear as papules, plaques, nodules, or ulcers, typically with wide-
spread distributions [4, 6]. Pulmonary disease is also common: 86% of patients had abnormal
chest X-rays in a series from South Africa [6]. Chest radiograph abnormalities have included
diffuse reticulonodular disease, consolidation, effusions, and/or lymphadenopathy [6]. Other
sites of disease that have been reported include the gastrointestinal tract, liver, lymph nodes,
and bone marrow [6]. Limited pulmonary disease has rarely been described, observed in the
sole reported case of disease caused by Es. europaeus [19]. For other species, all reported cases
have involved disseminated disease. This may reflect a diagnostic bias in clinical practice due
to late disease presentation and limited access to more invasive (e.g., bronchoscopic) pulmo-
nary sampling in resource limited settings or reporting bias in the medical literature.
The diagnosis of emergomycosis can be made by biopsy of affected tissue for histopathology
and fungal culture. Histopathology findings include small (2–5-μm) yeasts with narrow-based
budding, best seen with fungal stains [4]. The findings are insufficiently distinct from H. capsu-
latum to allow definitive identification from histopathological appearance alone [5]. The diag-
nosis can be confirmed by culture of Emergomyces species from clinical samples. Where fungal
cultures are negative (or omitted), PCR of fresh, affected tissue using amplification and
sequencing of the internal transcribed spacer (ITS) can establish the correct diagnosis [6, 9].
Emergomyces species grow readily on standard fungal media (e.g., Sabouraud agar, malt
extract agar, or potato dextrose agar), incubated at 24–30˚C. Colonies are yellowish white to
tan, initially glabrous, becoming powdery, slightly raised, and furrowed, and reach diameters
of 2.5 to 3.5 cm in 3 weeks. Microscopically, Emergomyces spp. are characterized in the mold
phase by slender conidiophores that arise from hyphae at right angles and form “florets” of
short secondary conidiophores bearing single small subspherical conidia (see Fig 2, step 1
[inset]). Conversion from the mold to the yeast phase occurs readily when colonies are
streaked onto potato dextrose agar or malt extract agar and incubated at 35˚C [8, 9, 17].
Clinical microbiologists should be aware that Emergomyces species can cross react with a
commercial DNA probe for B. dermatitidis [17]. There are neither sensitive nor specific sero-
logical tests nor biomarkers for the diagnosis of emergomycosis, though cross-reactivity can be
observed with tests for related fungal infections [5, 6]. Emergomyces species may cross react
with Histoplasma urinary antigen tests [5, 6], but a negative test cannot exclude the diagnosis:
in a series of 10 patients with culture-proven emergomycosis, only 3 tested positive by Histo-
plasma urinary antigen test [5].
Current treatment recommendations for emergomycosis are based on observational studies
and expert opinion and are the same as those for patients with histoplasmosis [6, 23]. Initially,
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immunocompromised patients with emergomycosis should be treated with amphotericin B
for 10–14 days; where available, liposomal formulations are preferred over deoxycholate
because of a more favorable toxicity profile. Thereafter, patients should be treated with itraco-
nazole or another newer azole for 12 months pending immune reconstitution. Fluconazole
should be avoided because high minimum inhibitory concentrations have been observed [7,
17, 24]. Among HIV-infected persons with emergomycosis who are antiretroviral therapy
(ART)–naive (or on a failing ART regimen), the optimal timing of ART initiation (or modifi-
cation) has not been established.
Pathogenesis
There remains much to learn about the virulence factors of these fungi and pathogenesis
involved in infection. Known virulence factor genes of dimorphic fungi are conserved in Es.
africanus and Es. pasteurianus [25]. The role of these in Emergomyces pathogenesis still needs
to be evaluated. Strains of Es. africanus, Es. europaeus, and Es. pasteurianus (but not Es. cana-
densis or Es. orientalis) express urease [8, 26], a known virulence factor for some pathogenic
fungi like Cryptococcus neoformans and C. gattii. Experimental infections have demonstrated
susceptibility of golden hamsters and mice [20, 27]. Schwartz and colleagues found that intra-
peritoneal inoculations with Es. africanus were fatal to wild-type mice at doses of 106 conidia,
whereas lower doses did not cause disease (although the organism could still be cultured from
their livers and spleens with inoculae as low as 102 conidia) [20]. Moreover, C57BL/6 mice
were more susceptible to disease than BALB/c mice [20]. Further work is underway to under-
stand the pathogenesis of disease and the immunology of infection.
Future directions
There are many unresolved questions about Emergomyces. The true geographic range of Emer-
gomyces species remains speculative, given the sporadic reports of disease from areas with lim-
ited mycological diagnostic capacity. For example, a case of emergomycosis caused by Es.
pasteurianus in Uganda was diagnosed after a visiting doctor returned to Germany with a skin
biopsy specimen that was collected from a Ugandan patient with a disseminated mycosis [16].
There, the diagnosis was made by nucleic acid amplification and sequencing, technology lack-
ing in most African settings. It is presumed that this case and those diagnosed in South Africa
represent the “ears of the hippo” on the African continent and that many other cases there and
possibly on other continents go unrecognized. The development of an affordable, accessible,
and feasible diagnostic test for emergomycosis should be prioritized to enable the diagnosis in
places where the disease is widespread and to detect the presence of it elsewhere for epidemio-
logical surveillance.
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